Aardvark Therapeutics, Inc., was incorporated in Delaware on May 17, 2017. The company is a clinical-stage biopharmaceutical company that develops small molecule therapies targeting bitter receptors to activate the innate homeostasis pathway in metabolic diseases. Its lead drug candidate, ARD-101, an oral, gut-limited agonist, is being studied for Prader-Willi syndrome-related hyperphagia, and its Phase 3 trial has been voluntarily suspended for data review.
